Life Science News

BeiGene (NASDAQ:BGNE;HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of patients with relapsed/refractory …

BeiGene (NASDAQ:BGNE;HKEX:06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, for the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

As quoted in the press release:

Zanubrutinib was discovered in BeiGene’s research facilities in Beijing, China, and is being developed globally by BeiGene as a monotherapy and in combination with other therapies to treat various hematologic malignancies. In August, the NMPA accepted BeiGene’s first NDA for zanubrutinib for the treatment of patients with R/R mantle cell lymphoma (MCL).

“Our team has made three NDA submissions in China this year, including two for zanubrutinib and one for tislelizumab, our investigational anti-PD-1 antibody. We are hopeful that these submissions, if approved, could further transform BeiGene as well as bring important new treatment options to cancer patients,” commented John Oyler, co-founder, CEO and Chairman of BeiGene.

“We are delighted that the submission for zanubrutinib in patients with relapsed/refractory CLL/SLL was accepted by the NMPA in China, and we are excited to announce the top-line pivotal data for zanubrutinib in these patients, which demonstrated a high overall response rate of 80 percent despite a relatively short follow-up. These results in China are also consistent with the data from our global studies,” said Dr. Xiaobin Wu, General Manager of China and President of BeiGene, Ltd.

Click here to read the full press release.

MARKETS

Markets
TSX19545.02+39.69
TSXV652.78-1.98
DOW32623.37+227.20
S&P 5004128.40+37.21
NASD12540.36+191.60
ASX6998.10+5.10

COMMODITIES

Commodities
Gold1768.16+11.82
Silver20.08+0.22
Copper3.50-0.01
Palladium2025.00-29.00
Platinum904.00+12.00
Oil94.60+0.18
Heating Oil3.47+0.09
Natural Gas7.70-0.01

DOWNLOAD FREE REPORTS

×